Topic

CTXR

A collection of 2 issues

D. Boral Capital Upgrades Citius Pharmaceuticals to Buy

D. Boral Capital has upgraded Citius Pharmaceuticals (CTXR) stock to Buy from Hold, citing Lymphir's imminent commercialization with a $9 price target.

Citius Pharmaceuticals Upgraded to Buy with $9 Target

Citius Pharmaceuticals (CTXR) gets a Buy upgrade from D. Boral Capital with a $9 price target, driven by the anticipated commercialization of Lymphir.